News View All News arrow-button

Jun 05, 2018

CEO Gary Glick Gives Insight into the Science and Opportunity of NLRP3 Inhibition

IFM Therapeutics CEO Gary Glick recently commented in Xconomy on the scientific advances related to inflammation drug development.  

Glick, who has been an Xconomy contributor or “Xconomist” for eight years, discussed the opportunity around developing antagonists that target the NLRP3 inflammasome—known to be a source of inflammatory responses in auto-immune diseases and other serious, chronic illnesses. His op-ed also highlighted what’s on the horizon for patients, and the potential upside of treatments that selectively target abnormal inflammation as opposed to current therapies that suppress immune response. 
View the full story, "The Revolution in Inflammation Drug Development”, on Xconomy. 

Media Contact

Amanda Sellers
Spectrum Science Communications